 |
市場調查報告書
商品編碼
2039072
BRAF激酶抑制劑市場：依藥物、適應症、通路和地區分類。BRAF Kinase Inhibitors Market, By Drug, By Indication, By Distribution Channel, By Geography |
||||||
BRAF激酶抑制劑市場預計在2026年達到21.2億美元，預計到2033年將達到35.2億美元。預計從2026年到2033年，其複合年成長率將達到8.3%。
| 報告範圍 | 報告詳情 | ||
|---|---|---|---|
| 基準年： | 2025 | 2026年市場規模： | 21.2億美元 |
| 歷史數據時期： | 2020年至2024年 | 預測期： | 2026年至2033年 |
| 2026年至2033年預測期間的複合年成長率： | 8.30% | 2033年市場規模預測： | 35.2億美元 |
BRAF是一種激酶，在調節細胞增殖和訊號傳導中發揮作用。在某些癌症中，例如黑色素瘤和結直腸癌，BRAF以突變（改變）形式存在。抑制突變的BRAF激酶蛋白可能抑制癌細胞增生。一些BRAF激酶抑制劑用於治療癌症。大約50%的黑色素瘤存在活化型BRAF突變（超過90%為V600E突變）。 BRAFV600E被認為參與黑色素瘤發生的多種機制，其中許多機制是由於下游MEK/ERK效應因子的不受控制的活化所致。兩種化合物（Vemurafenib和Dabrafenib）已獲得美國食品藥物管理局（FDA）核准，用於治療轉移性和不可切除的BRAF突變型黑色素瘤。
市場動態
BRAF激酶抑制劑市場的領導者正專注於專利收購，預計將為新興市場的BRAF激酶抑制劑生產商創造更多機會。例如，2016年9月，諾華國際公司在印度獲得了其皮膚癌（黑色素瘤）治療藥物Tafinlar的專利。該藥物用於治療轉移性黑色素瘤，這是一種存活率低、最嚴重且危及生命的皮膚癌。
然而，BRAF激酶抑制劑市場面臨的挑戰之一是患者的用藥依從性。 BRAF激酶抑制劑的高昂費用導致患者放棄其主要治療方法，轉而選擇其他癌症治療方法。預計在不久的將來，其他癌症治療方案的出現將阻礙BRAF激酶抑制劑市場的成長。例如，轉移性癌症需要全身性治療和藥物，如化療和荷爾蒙療法，這些藥物透過口服或靜脈注射注射給藥，以到達全身各處的癌細胞。其他治療方法包括免疫療法、放射線治療、手術或這些療法的合併應用。
本次調查的主要特點
- 本研究確定了各個細分市場的潛在商機，並說明了該市場具有吸引力的投資提案矩陣。
- 此外，本研究還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要參與者採取的競爭策略的重要見解。
- 本研究根據以下參數對全球 BRAF 激酶抑制劑市場的主要參與者進行了分析：公司概況、財務表現、產品系列、地理企業發展、分銷策略、關鍵發展和策略。
- 透過利用本報告中的見解，企業負責人和經營團隊將能夠就未來的產品發布、政府舉措、技術升級、市場擴張和行銷策略做出明智的決策。
- 這份全球 BRAF 激酶抑制劑市場報告的目標相關人員廣泛，包括投資者、產品製造商、經銷商、供應商、研究和諮詢公司、新參與企業和金融分析師。
目錄
第1章：研究目標與前提條件
- 研究目標
- 前提
- 簡稱
第2章 市場範圍
- 報告摘要
- 市場定義和範圍
- 執行摘要
- Coherent Opportunity Map（COM）
第3章：市場動態、監管與趨勢分析
- 市場動態
- 促進因素
- 阻礙因素
- 市場機遇
- 影響分析
- 市場趨勢
- 主要進展
- 產品核准
- 合作關係、併購
- 監理情勢
- PEST分析
- 波特五力分析
- 流行病學
- 固體管道分析
第4章 全球BRAF激酶抑制劑市場：依藥物分類，2021-2033年
- Vemurafenib
- Dabrafenib
- 利非拉非尼
- Encorafenib
第5章 全球BRAF激酶抑制劑市場：依適應症分類，2021-2033年
- 轉移性黑色素瘤
- 轉移性肺癌
- 其他
第6章 全球BRAF激酶抑制劑市場：依通路分類，2021-2033年
- 醫院藥房
- 零售藥房
- 網路藥房
第7章 全球BRAF激酶抑制劑市場：依地區分類，2021-2033年
- 北美洲
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
- 歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
- 亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 亞太其他地區
- 中東
- GCC
- 以色列
- 其他中東國家
- 非洲
- 北非
- 中非
- 南非
第8章 競爭情勢
- 熱圖分析
- 市佔率分析
- 公司簡介
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- Array BioPharma Inc.（Pfizer）
- Bayer AG
- Plexxikon Inc.（Daiichi Sankyo）
- Blueprint Medicines
- Kinnate Biopharma Inc.
- IDEAYA Biosciences
- Mirati Therapeutics
- Loxo Oncology（Eli Lilly）
- BeiGene Ltd.
- Spectrum Pharmaceuticals
- Ono Pharmaceutical
- Chugai Pharmaceutical
- BridgeBio Pharma
第9章
- 參考
- 調查方法
- 關於本公司
Braf Kinase Inhibitors Market is estimated to be valued at USD 2.12 Bn in 2026 and is expected to reach USD 3.52 Bn by 2033, growing at a compound annual growth rate (CAGR) of 8.3% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 2.12 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 8.30% | 2033 Value Projection: | USD 3.52 Bn |
BRAF is a kinase enzyme that helps control cell growth and signalling. It may be found in a mutated (changed) form in some types of cancer, including melanoma and colorectal cancer. Blocking mutated BRAF kinase proteins may help keep cancer cells from growing. Some BRAF kinase inhibitors are used to treat cancer. About 50 % of melanomas harbors activating BRAF mutations (over 90 % V600E). BRAFV600E has been implicated in different mechanisms underlying melanomagenesis, most of which due to the deregulated activation of the downstream MEK/ERK effectors. Two compounds (vemurafenib and dabrafenib) have achieved approval by the Food and Drug Administration (FDA) for the treatment of metastatic and unresectable BRAF-mutated melanomas.
Market Dynamics
Key players in the BRAF kinase inhibitors market are focusing on obtaining patents, which is expected to create more opportunities for BRAF kinase inhibitor drugs manufacturers in the emerging economies. For instance, in September 2016, Novartis International AG secured an Indian patent for its skin cancer (melanoma) drug Tafinlar, which is used for the treatment of metastatic melanoma, the most serious and life-threatening type of skin cancer that is associated with low survival rates.
However, one of the challenges in BRAF kinase inhibitors market is patient adherence. Due to the high cost of BRAF kinase inhibitor drugs, patients are shifting from the actual treatment regime to alternatives of cancer treatments. Alternative methods available for cancer treatments is expected to hinder growth of the BRAF kinase inhibitors market in the near future. For instance, metastatic cancer requires systemic therapy or medications given through mouth or injected into the bloodstream to reach cancer cells throughout the body such as chemotherapy or hormone therapy. Other treatments may include immunotherapy, radiation therapy, surgery or a combination of these.
Key features of the study
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
- It profiles key players in the global BRAF kinase inhibitors market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
- Key players covered as a part of this study include F. Hoffmann-La Roche AG, Novartis International AG, and Pfizer, Inc.
- Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
- The global BRAF kinase inhibitors market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for BRAF kinase inhibitors market, research and consulting firms, new entrants, and financial analysts.
Market Segmentation
- By Drug
- Vemurafenib
- Dabrafenib
- Lifirafenib
- Encorafenib
- By Indication
- Metastatic Melanoma
- Metastatic Lung Cancer
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Key Players
- Hoffmann-La Roche Ltd.
- Novartis AG
- Array BioPharma Inc. (Pfizer)
- Bayer AG
- Plexxikon Inc. (Daiichi Sankyo)
- Blueprint Medicines
- Kinnate Biopharma Inc.
- IDEAYA Biosciences
- Mirati Therapeutics
- Loxo Oncology (Eli Lilly)
- BeiGene Ltd.
- Spectrum Pharmaceuticals
- Ono Pharmaceutical
- Chugai Pharmaceutical
- BridgeBio Pharma
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug
- Market Snapshot, By Indication
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Product Approval
- Collaboration/Merge/Acquisition
- Regulatory Landscape
- PEST Analysis
- Porter's Five Forces Analysis
- Epidemiology
- Robust Pipeline Analysis
4. Global BRAF Kinase Inhibitors Market, By Drug, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
- Vemurafenib
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Dabrafenib
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Lifirafenib
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Encorafenib
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
5. Global BRAF Kinase Inhibitors Market, By Indication, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Metastatic Melanoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Metastatic Lung Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
6. Global BRAF Kinase Inhibitors Market, By Distribution Channel, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
7. Global BRAF Kinase Inhibitors Market, By Region, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (USD Billion)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Company Profile
- F. Hoffmann-La Roche Ltd.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Array BioPharma Inc. (Pfizer)
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Bayer AG
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Plexxikon Inc. (Daiichi Sankyo)
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Blueprint Medicines
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Kinnate Biopharma Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- IDEAYA Biosciences
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Mirati Therapeutics
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Loxo Oncology (Eli Lilly)
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- BeiGene Ltd.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Spectrum Pharmaceuticals
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Ono Pharmaceutical
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Chugai Pharmaceutical
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- BridgeBio Pharma
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Analyst Views
9. Section
- References
- Research Methodology
- About Us
